Ultimately, two potentially pharmacologically targetable genes, P2RY14 (PP.H4 = 0.917) and ATRAID (PP.H4 = 0.860), were identified as having a common genetic effect between eQTLs and IBS risk (Figure 3). The gene discussed is P2RY14; the disease is irritable bowel syndrome.